- Home
- Companies
- MedGenome Inc.
- Products
- MedGenome - Model OncoPeptTUME - ...
MedGenome - Model OncoPeptTUME - Immunotherapy Drugs
OncoPeptTUME — A novel in-silico approach to model the tumor microenvironment and predict treatment efficacy and long-term survival benefits for immunotherapy applications. Cancer immunotherapy is now established as a major therapeutic modality. Cancer immunotherapy drugs elicit their anti-tumor immune response in a subset of the treated patients by activating CD8 T-cells and provide sustainable and long-lasting benefit in a few.
Recently, significant efforts have been devoted to understanding the factors that influence response to immuno-therapy and/or contribute to the development of resistance to therapy. While it is appreciated that many different tumor cell- intrinsic and extrinsic features, including the tumor microenvironment, driver gene mutations, host genetics, microbiome and environmental factors modulate response to immune checkpoint inhibitors, the tumor microenvironment ecosystem could be a major contributor in regulating response to immunotherapy and development of resistance.